Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 673 clinical trials
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer (IPLA-OVCA)

Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour

surgery for ovarian cancer
cancer of the ovary
ovarian cancer stage
cytoreductive surgery
  • 11 Jul, 2022
  • 1 location
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in china.

  • 25 May, 2021
  • 1 location
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

patients with recurrent, platinum-resistant primary epithelial ovarian cancer, fallopian tube cancer or peritoneal carcinoma.

  • 14 Oct, 2021
  • 1 location
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer (SABR-ROC)

Rationale Ovarian cancer is the 3rd most common gynecologic malignancy in Korea. The standard treatment is tumor debulking surgery with or without adjuvant chemotherapy. However, with a

  • 04 Oct, 2022
  • 1 location
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

This study aims to investigate the effect of involved-field radiotherapy for recurrent ovarian cancer after primary standard treatment. We will investigate whether the addition of involved-field

neutrophil count
ovarian carcinoma
  • 12 Feb, 2022
  • 1 location
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if

  • 04 Oct, 2022
  • 3 locations
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite

  • 04 Oct, 2022
  • 1 location
Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE)

participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). This study has an umbrella design. The trial consists of dose escalation (DES) and expansion

  • 07 Oct, 2022
  • 12 locations
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.

  • 17 Dec, 2021
  • 2 locations
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

, ovarian cancer and mesothelioma. This feasibility study consists of two parts: (a) a dose escalation phase to select the optimal dose followed by (b) enrollment of additional patients to develop the tumor

  • 07 Feb, 2022
  • 1 location